Showing results (231-240 of 264) with videos related to

Sort By:
Pageof 27
Health Technology Assessment (Winchester, England)|October 27, 2022
Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCTRakesh Heer, Rebecca Lewis, Anne Duncan, et al.
European Urology|July 20, 2026
Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B TrialSian Cooper, Jaymini Patel, Caroline Moore, et al.
BJC Reports|November 8, 2024
Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genesSarah Benafif, Ann-Britt Jones, Susan Merson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trialChristopher M Nutting, Clare L Griffin, Paul Sanghera, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2018
Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)Christopher M Nutting, James P Morden, Matthew Beasley, et al.
The Journal of Clinical Investigation|June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancerJuliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
Clinical and Translational Radiation Oncology|December 1, 2022
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancerDavid J Thomson, Clare Cruickshank, Helen Baines, et al.
The Journal of Clinical Investigation|December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistanceJoaquin Mateo, George Seed, Claudia Bertan, et al.
Cancer Discovery|September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Ebiomedicine|August 13, 2016
Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate CancerSarah L Kerns, Leila Dorling, Laura Fachal, et al.
Pageof 27